Valuation: Relay Therapeutics, Inc.

Market Cap 4.11B 3.65B 3.41B 3.09B 5.84B 396B 5.88B 40.97B 15.94B 202B 15.41B 15.08B 649B P/E 2026 *
-11.7x
P/E 2027 * -11.6x
Enterprise Value 3.54B 3.14B 2.94B 2.66B 5.03B 341B 5.06B 35.28B 13.72B 174B 13.27B 12.99B 559B EV / Sales 2026 *
317x
EV / Sales 2027 * 204x
Free-Float
91.39%
Yield 2026 *
-
Yield 2027 * -
1 day-3.35%
1 week+2.07%
Current month+3.82%
1 month-1.58%
3 months-0.85%
6 months+50.52%
Current year+121.51%
1 week 17.86
Extreme 17.86
19.5
1 month 17.05
Extreme 17.05
19.69
Current year 7.01
Extreme 7.01
21.27
1 year 5.83
Extreme 5.83
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
37.67
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 2017-02-28
Director of Finance/CFO 49 2018-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 2015-05-03
Director/Board Member 66 2016-06-30
Director/Board Member 52 2017-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Sell

Chief Financial Officer

-17,717 0.0081%
9/8/26 Sell

Chief Executive Officer

-48,199 0.0220%
9/8/26 Sell

Chief Technology Officer

-8,530 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-3.35%+2.07%+235.24%+126.06% 4.25B
+4.16%+4.16%+49.37%+94.17% 74.31B
+2.76%-1.60%+22.80%+78.53% 56.95B
+0.24%-1.34%+3.41%+34.31% 48.3B
-3.76%-2.25%+329.09%+698.20% 44.51B
-2.30%-3.35%+26.81%+30.88% 43.8B
+0.31%-0.68%+5.30%+108.64% 41.12B
-0.11%+1.96%+9.19%+52.66% 31.07B
-3.37%-0.54%+32.74%+24.16% 28.97B
-1.96%-2.88%-8.97%-13.92% 24.53B
Average -0.77%-0.47%+70.50%+123.37% 39.78B
Weighted average by Cap. +0.12%-0.89%+58.28%+132.11%

Financials

2026 *2027 *
Net sales 11.16M 9.91M 9.27M 8.4M 15.87M 1.08B 15.98M 111M 43.31M 549M 41.89M 40.99M 1.76B 17.94M 15.92M 14.9M 13.51M 25.51M 1.73B 25.69M 179M 69.61M 882M 67.33M 65.89M 2.84B
Net income -320M -284M -266M -241M -455M -30.86B -459M -3.19B -1.24B -15.74B -1.2B -1.18B -50.61B -347M -308M -289M -262M -494M -33.48B -497M -3.47B -1.35B -17.08B -1.3B -1.28B -54.91B
Net Debt -571M -507M -474M -430M -812M -55.01B -817M -5.69B -2.21B -28.06B -2.14B -2.1B -90.22B -442M -392M -367M -333M -629M -42.61B -633M -4.41B -1.72B -21.74B -1.66B -1.62B -69.88B
Projected Income Statement - Annual - Relay Therapeutics, Inc.
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
26-10-06 US$18.74 -3.35% 3,871,063
26-10-05 US$19.39 +2.27% 2,936,413
26-10-02 US$18.96 +2.54% 2,770,998
26-10-01 US$18.49 +2.44% 2,824,167
26-09-30 US$18.05 -1.69% 2,782,511
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Relay Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
18.74USD
Average target price
27.58USD
Spread / Average Target
+47.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Relay Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RLAY Stock